Charcoal, Activated

Charcoal, Activated

SCHEMBL958696

[C].[P].[P]

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240209520-A1 APPARATUS FOR MANUFACTURING NITROGEN-CONTAINING COMPOUND AND METHOD FOR MANUFACTURING NITROGEN-CONTAINING COMPOUND IDEMITSU KOSAN CO.,LTD. (JP) 2024-06-27 US disclosed
EP-4332270-A1 APPARATUS FOR MANUFACTURING NITROGEN-CONTAINING COMPOUND AND METHOD FOR MANUFACTURING NITROGEN-CONTAINING COMPOUND Idemitsu Kosan Co., Ltd (JP) 2024-03-06 EP disclosed
CN-117242206-A Nitrogen-containing compound production apparatus and nitrogen-containing compound production method 出光兴产株式会社 2023-12-15 CN disclosed
EP-3384900-B1 STABLE DOSAGE FORM OF ETIDRONATE-CYTARABINE CONJUGATE MAXWELL BIOTECH GROUP LTD (RU) 2023-08-09 EP disclosed
WO-2023033185-A1 METHOD FOR PRODUCING AMMONIA, MOLYBDENUM COMPLEX USED IN SAID PRODUCTION METHOD, AND LIGAND THAT IS STARTING MATERIAL FOR SAID MOLYBDENUM COMPLEX 国立大学法人東京大学 2023-03-09 WO disclosed
WO-2022230896-A1 APPARATUS FOR MANUFACTURING NITROGEN-CONTAINING COMPOUND AND METHOD FOR MANUFACTURING NITROGEN-CONTAINING COMPOUND 出光興産株式会社 2022-11-03 WO disclosed
US-11219603-B2 Stable dosage form of etidronate-cytarabine conjugate, and use thereof MAXWELL BIOTECH GROUP LTD. (RU) 2022-01-11 US disclosed
US-20210379108-A1 CAR T-CELLS FOR THE TREATMENT OF BONE METASTATIC CANCER H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. 2021-12-09 US disclosed
US-11045487-B2 Pharmaceutical preparation treating bone lesions caused by malignant neoplasms MAXWELL BIOTECH GROUP LTD. (RU) 2021-06-29 US disclosed
US-20210177903-A1 CAR T-CELLS FOR THE TREATMENT OF BONE METASTATIC CANCER H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. 2021-06-17 US disclosed
US-6572874-B1 For treatment of osteoporosis and related bone and skeleton diseases; alendronate, clodronate, etidronate, pamidronate, tiludronate, ibandronate, neridronate, risedronate, zoledronate and olpadronate UMD, INC. 2003-06-03 US disclosed
EP-1311213-A1 VAGINAL DELIVERY OF BISPHOSPHONATES UMD, Inc. (US) 2003-05-21 EP disclosed
EP-1131100-B1 THERAPEUTIC COMPOSITIONS FOR METABOLIC BONE DISORDERS OR BONE METASTASES COMPRISING A PHOTOSENSITIZER AND A BISPHOSPHONATE LIGHT SCIENCES CORP (US) 2003-03-12 EP disclosed
US-20030018371-A1 Compositions and methods for the treatment of metabolic bone disorders and bone metastases LIGHT SCIENCES CORPORATION 2003-01-23 US disclosed
US-20020142997-A1 Liquid pharmaceutical composition for treating bone diseases RIDERWAY CORPORATION 2002-10-03 US disclosed
WO-2002070438-A2 COMPOSITIONS FOR DELIVERING BISPHOSPHONATES EMISPHERE TECHNOLOGIES, INC. (US) 2002-09-12 WO disclosed
EP-1228761-A2 Liquid pharmaceutical composition for treating bone diseases Riderway Corporation (PA) 2002-08-07 EP disclosed
WO-2002009631-A1 VAGINAL DELIVERY OF BISPHOSPHONATES UMD, INC. (US) 2002-02-07 WO disclosed
EP-1131100-A2 THERAPEUTIC COMPOSITIONS FOR METABOLIC BONE DISORDERS OR BONE METASTASES Light Sciences Corporation (US) 2001-09-12 EP disclosed
WO-2000041725-A2 THERAPEUTIC COMPOSITIONS FOR METABOLIC BONE DISORDERS OR BONE METASTASES LIGHT SCIENCES CORPORATION (US) 2000-07-20 WO disclosed